Compare Flagstar Bank NA (FLG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Viatris Inc — how do they compare? Flagstar Bank NA trades at $14.16 (market cap $5.90B), while Viatris Inc trades at $16.1 (market cap $18.49B). The key difference: Viatris Inc is far larger — about 3.1× Flagstar Bank NA's market cap, and Viatris Inc pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| FLG | VTRS | |
|---|---|---|
Market Cap | $5.90B | $18.49B |
Sector | Financials | Health |
52-Week High | $15.36 | $17.86 |
52-Week Low | $10.72 | $9.49 |
Dividend Yield | 0.28% | 2.98% |
Enterprise Value | — | $30.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.21, up 0.14% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Recent news highlights strategic initiatives like a $250 million share buyback and dividend declarations. Fundamentals reveal a low P/B of 0.77 but a high P/E of 473.67, with net income turning positive in 2026. The company's cash flow improved, though net cash flow remains negative.
Outlook is cautiously optimistic with a consensus price target of $16.85, offering 18.6% upside. Risks include earnings volatility, high P/E valuation, and macroeconomic sensitivity. The bullish analyst consensus and institutional buy-in support potential growth, but investors should monitor execution on profitability targets.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
